Recent Posts in ‘Regenerative Medicine’
Advanced Cell Technology Announces Approval of Wills Eye Institute as Additional Site
Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Wills Eye Institute in Philadelphia has received institutional review board (IRB) approval as a site for the company’s Phase I/II clinical trial for Stargardt’s Macular Dystrophy (SMD), a form of juvenile macular degeneration, using human embryonic
Regenerative Medicine Stocks Bring Some Love to BIO CEO Conference on Valentine’s Day
Athersys, Inc. (NASDAQ: ATHX), StemCells Inc. (NASDAQ: STEM) and other regenerative medicine companies are presenting at the 14th Annual 2012 BIO CEO Investor Conference on Monday, February 13 and Tuesday, February 14 in New York City. Webcast replays of these presentation will be available on the companies’ websites, www.athersys.com and www.stemcellsinc.com. The presentation times for
Cytomedix (CMXI) Expands Regenerative Medicine Portfolio with Aldagen Acquisition
Cytomedix, Inc. CMXI (the “Company”), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, announces the completion of the acquisition of Aldagen, Inc., a privately-held biopharmaceutical company developing regenerative cell therapies based on its proprietary ALDH bright cell (“ALDHbr”) technology. Under the terms of the transaction as described below, Cytomedix
American CryoStem Joins Alliance for Regenerative Medicine
American CryoStem Corporation (otcqb:CRYO), a commercial developer, manufacturer and marketer of clinical products and services involving adipose tissue and adipose derived adult stem cells, announced its association with the Alliance for Regenerative Medicine (ARM). ARM is a Washington, DC-based non-profit organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances
Athersys (ATHX) Releases Positive Results from MultiStem(R) Clinical Trial for GvHD
Athersys Inc. (NASDAQ: ATHX), a biopharmaceutical company focused on developing an innovative stem cell platform, similar to companies like Mesoblast (ASX: MSB), Verastem Inc. (NASDAQ: VSTM) and Osiris (NASDAQ: OSIR), announced grant funding awards of $3.6 million earlier this morning to continue its research in neurological and cardiovascular disease areas, and now added positive results
Athersys (ATHX) Receives $3.6 Million Grant for Stem Cell Development
Athersys Inc. (Nasdaq: ATHX), a biopharmaceutical company focused on developing an innovative stem cell platform, similar to companies like Verastem Inc (Nasdaq: VSTM), Osiris (Nasdaq: OSIR) and ThermoGenesis Corp (Nasdaq: KOOL), recently received a $3.6 million grant to further advance its MultiStem® product programs and cell therapy platform. Athersys, Inc. (Nasdaq: ATHX), a leader in
Cardium (CXM) Presents Generx Findings at 2012 Gene and Cell Therapy Forum
Cardium Therapeutics (Amex: CXM), a developer and acquirer of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, similar to companies like Impax Laboratories Inc. (Nasdaq: IPXL) and Biogen Idec Inc. (Nasdaq: BIIB), will present new insights that support Generx Angiogenic
Verastem Prices Initial Public Offering
Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold
InvestorStemCell.com: Is Validation of Regenerative Medicine Upon the World for 2012?
Since the late 1990’s, the world has been told that using our own stem cells would someday lead to cures and treatments for unmet medical needs. ALS, Alzheimer’s, Parkinson’s, macular degeneration (AMD) and acute myocardial infarction (AMI) were on the short list of proposed therapeutic concentrations of research. Unfortunately in the excitement of an upcoming
RegenoCELL (RCLL): A Short- and Long-term Approach to Stem Cell Therapeutics
RegenoCELL Therapeutics Inc. (OTCBB: RCLL), a provider of stem cell therapy for congestive heart failure and developer of therapeutics for peripheral artery disease , differs from Aastrom Biosciences Inc. (NASDAQ: ASTM) or Advanced Cell Technology (OTCBB: ACTC.OB) in that it is already actively marketing its therapy and simultaneously developing a U.S./E.U. solution. Efficacious Treatment Already